Gland Pharma (GLAND) Share News & Alerts
Every article that mentions GLAND is analysed by our AI, which assigns a sentiment and tracks the actual price move after the alert fires.
Honasa Consumer, 6 other stocks hit 52-week highs, rally up to 35% in a month
▲ Bullish +2.05%
Reaching a 52-week high indicates a reversal of historical underperformance and a strong influx of long-term capital despite volatile market conditions. The price action confirms sustained accumulation, providing a high-probability setup for positional long trades targeting extended upside over a 1-3 month swing horizon.
Cenexi recovery, new product launches and capacity additions power Gland Pharma outlook
▲ Bullish +7.25%
Gland Pharma reported strong March quarter results driven by a recovery in its European subsidiary, Cenexi, and volume growth. New product launches and capacity expansions provide visible earnings growth, which is highly positive for swing and positional traders over a 1-to-3-month horizon as institutional buying continues.
Top Gainers & Losers on May 18: Gland Pharma, Coforge, PB Fintech, BSE, Voltas, Bharti Airtel among top gainers
▲ Bullish +6.42%
Gland Pharma emerged as a top gainer providing critical sectoral support to the benchmarks, indicating short-term defensive buying and positive price action in the pharma space.
Volumes spurt at Gland Pharma Ltd counter
▲ Bullish +6.47%
Gland Pharma is experiencing a major breakout catalyzed by Q4 net profits doubling year-on-year alongside expanding EBITDA margins. The massive volume surge confirms institutional backing for the upside move, making it a high-conviction long candidate. Expect this momentum to translate into a strong multi-week bullish swing towards targets near 2,300 as consensus earnings estimates get revised upward.
Gland Pharma Ltd leads gainers in 'A' group
▲ Bullish +11.4%
Gland Pharma reported an exceptional 96.6% year-on-year growth in Q4 FY26 net profit alongside robust revenue and margin expansions driven by its CDMO business. This massive earnings beat triggered sharp institutional accumulation, causing a powerful gap-up and rally over 14%. The significant operational recovery sets a strong bullish tone for multi-week swing and positional long strategies.
Gland Pharma shares jump 11% as Q4 profit soars 97% YoY, co announces Rs 20/share final dividend
▲ Bullish +6.73%
The company reported an exceptionally strong Q4 performance with net profit nearly doubling year-on-year, driven by robust growth in its core CDMO business. Combined with a sizeable Rs 20 per share dividend, this significant earnings beat serves as a major fundamental catalyst that is likely to drive a sustained multi-day bullish swing for the stock as institutional and retail investors re-rate the company's growth trajectory.
Gland Pharma share price jumps over 16% to 52-week high despite stock market crash. Should you buy the pharma stock?
▲ Bullish +7.18%
Gland Pharma is directly impacted by a strong earnings surprise and robust sales traction in the US market, which has triggered a massive 13-16% short-term price breakout. This strong fundamental catalyst provides a bullish structural shift, supporting a strong positive momentum for swing and positional traders over the next few weeks.
Gland Pharma spurts as Q4 PAT jumps 97% YoY to Rs 367 crore
▲ Bullish +11.41%
Gland Pharma reported an exceptional 96.6% YoY jump in its quarterly consolidated net profit along with strong margin expansion to 29.4%. This multi-quarter high operational efficiency is driven by strategic expansion in US and Europe generic spaces alongside key product rollouts like Liraglutide. For swing and positional traders, this strong fundamental turnaround provides a clear structural catalyst for an upward re-rating over a multi-week horizon.
Gland Pharma Q4 PAT jumps 97% YoY to Rs 367 crore
▲ Bullish +26.3%
The 97% profit surge significantly beats analyst expectations of ₹270-310 crore, providing a strong fundamental catalyst for a re-rating. Revenue growth of 22% and a healthy EBITDA margin of 29% indicate a sharp recovery in the core injectable business and successful global expansion. Given the stock's recent consolidation and attractive valuation of ~22x FY28E P/E, this 'clean' earnings beat is likely to trigger a bullish swing move over the next 1-2 weeks as institutional investors adjust their price targets.
Gland Pharma Ltd gains for third consecutive session
▲ Bullish +2.49%
The stock has cleared its 200-day Daily Moving Average (DMA) of ₹1,829, signaling a shift from a long-term bearish to a bullish phase. This technical momentum is being supported by pre-earnings positioning ahead of the May 15 financial results and dividend announcement. Given the recent volume-backed three-day rally, a swing trade setup is emerging toward the ₹1,970–₹2,000 resistance zone.
Get real-time alerts for GLAND
Add GLAND to your portfolio and receive instant AI-powered news alerts on your phone.
Set up free alerts →Explore More
AI Technical Analysis Alert History Other Bullish Stocks Today’s Trending